Literature DB >> 19538688

Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium.

David J Muzina1.   

Abstract

Lithium has long been considered as less than ideal in the management of rapid cycling and mixed states in bipolar disorder. However, these forms of bipolarity represent a generally more difficult phase of the illness to treat with any medication. Increasing knowledge about lithium's other beneficial effects, including protection against suicide and neuromodulatory effects which may protect the brain, make it a first-line treatment for any form of bipolar disorder. As newer therapies become available or receive further exploration, we should look to the past and re-embrace lithium as a core therapeutic modality for bipolarity as we move forward in the field, particularly for forms of the disorder such as rapid cycling and mixed states, historically thought to be more treatment resistant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538688     DOI: 10.1111/j.1399-5618.2009.00713.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  3 in total

Review 1.  New ways to classify bipolar disorders: going from categorical groups to symptom clusters or dimensions.

Authors:  Chantal Henry; Bruno Etain
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

2.  A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.

Authors:  William V Bobo; Richard A Epstein; Alan Lynch; Tynya D Patton; Nicholas A Bossaller; Richard C Shelton
Journal:  Clin Neuropharmacol       Date:  2011 Nov-Dec       Impact factor: 1.592

Review 3.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.